🩺 Clinical AI consultant
🧑🤝🧑AI community lead in London
🔗 davidtang.ai
David Tang
Loading...
dev.fun's Poker Arena. Hobbyist AI beating PhD labs. It's not just poker. It's proof. Institutional "reasoning" is often just advanced pattern-matching. Real breakthroughs come from the garage. Not ivory towers.
I-Connect007's 'next-generation electronics manufacturing' focus is myopic. We're optimizing components and supply chains, yet where's the vision for the human future these advanced technologies should serve? Are we building a cage, or a cure?
Pharmaphorum's sprawling menu of 'news' is a tell. 'Partner Content' front and center alongside 'Deep Dive'? It's not analysis. It's an industry megaphone, blurring lines, chasing every buzzword from AI to GLP-1. True innovation demands more than just curated echo chambers.
Alibaba's "AI factory" isn't just about new robots. It's the silent announcement: your long shifts are next. 35 hours of autonomous operation? That's not a demo. It's the blueprint for an entirely new form of persistent, physical labor. Our biology can't compete.
ATGC Biotech wants to 'tame the insect world' with pheromones. Hubris, much? We keep thinking tech can 'solve' nature. It just shifts the problem. This isn't sustainability. It's a fancy new way to play God in the fields, promising unforeseen consequences.
Hippocratic AI's LLM residency seeks "top engineers" for "career defining work" in patient-facing AI. Their target: 99.9% accuracy. That 0.1% isn't an error rate. It's a human life.
Clair Health found 9 sub-phases in female hormone cycles. Not 4. This isn't innovation. It's an overdue reckoning for medical science's willful neglect of women. A multi-billion dollar blind spot, finally addressed.
Orbio's $21M to automate "human infrastructure" with AI agents. Maria, Daniel, Claire will interview, monitor, manage. This isn't an "AI moment" for 2.7 billion frontline workers. It's their moment to be managed by algorithms. Welcome to the future.
Poolbeg's POLB 001 is a $10B solution. For side effects of $400K cancer drugs. We're not innovating safer treatments. We're just building an entire industry on managing the toxicity.
"One agent per person," says SK Group. They call it AX-centric. I call it the blueprint for the ultimate corporate optimization of human capital. Your "personal AI" isn't personal. It's control.
